82 results about "Competitive immunoassay" patented technology

The invention provides microfluidic competitive immunoassay devices and assay methods for rapid, quantitative measurement of binding interactions between analytes and the quantitative determination of an amount (e.g., concentration) of the analyte in an unknown sample.

The present invention is intended to devise a process of measuring β-amyloid in a biological sample such as blood and to apply the process to diagnosis of Alzheimer's disease.It is possible to assay Alzheimer's disease by measuring a total amount of β-amyloid 1-42 and β-amyloid 1-42 fragments each of which retains a C-terminal site of the β-amyloid 1-42 in the biological sample by an immunological assay in which an antibody which recognizes the C-terminal site of β-amyloid 1-42 is used. It is preferable that the immunological assay be a competitive immunological assay.

Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone / paliperidone in a single lateral flow assay device.

The invention is directed to methods and devices for reducing interference from leukocytes in an competitive analyte immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads opsonized for leukocytes; and (b) performing a competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.

The present invention relates to a method for preparing haptens of formulae I and II that are useful in the preparation of immunogens, antibodies and conjugates, for use in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine. The haptens are prepared by reacting a phenylethanolamine derivative of formula D with a phenylalkylcarbonyl derivative of formula E: in which, in formula I, Z1 is a crosslinker and Z2 is H and, in formula II, Z1 is H and Z2 is a crosslinker.

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone / paliperidone in a single lateral flow assay device.

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

The present invention concerns a method for determining the concentration of calprotectin in a sample. A lateral flow test kit and test element using said method are also provided.

The present invention provides ligand-detection reagents, ligand analogs and methods for determining the presence of a ligand in a sample. The ligand-detection reagent comprises a ligand-binding antibody and a ligand analog to form an antibody-ligand analog complex wherein the ligand analog is covalently bonded to a reporter molecule. This complex may additionally comprise a labeling protein non-covalently bonded to the antibody to form a ternary complex wherein the labeling protein comprises a monovalent antibody fragment or a non-antibody protein that is covalently bonded to a label moiety. The reporter molecule is either quenched by the ligand-binding antibody or by the label moiety of the labeling protein, depending on the reporter molecule and the ligand-binding antibody, wherein the amount of quenching is directly related to the amount of ligand present in the sample. Alternatively, the ligand analog is fluorogenic wherein the ligand analog is essentially non-fluorescent in solution but when bound by the ligand-binding antibody the detectable signal increases. In this instance a decrease in signal, as opposed to the relieving of quenching, is measured for the presence of a target ligand.

An immunoassay apparatus on a chip is disclosed, which can quantitatively measure the concentration of hormones (particularly corticosterone and progesterone) in a biological sample. Such an apparatus can be designed to be used in the field, saving time and money for those taking the measurements. The measurements are made within a micro-fluidic channel configured on a substrate of a chip, which is loaded using simple capillary forces. Competitive immunoassay can be performed, with the competing agents being the hormone (e.g., antigen) and hormone-coated latex beads (e.g., both pre-mixed in a methanol solution).

The invention provides a multi-component direct-competitive immunoassay method for labeling haptens by using quantum dots of micromolecule organic matters and relates to a multi-component direct-competitive immunoassay technology. The multi-component direct-competitive immunoassay method comprises the following steps of: labeling different target analyte haptens by using the highly-efficient water-soluble quantum dots with different fluorescence emission wavelengths, taking polystyrene magnetic microspheres on which different antibodies are fixed and commonly dispersing corresponding target analyte prototypes as well as the haptens labeled by the corresponding quantum dots in phosphate buffer solution to carry out competitive immune response; and quickly separating the polystyrene magnetic microspheres from a liquid phase in a magnetic field by using a reaction balance system, carrying out fluorescence scanning or multi-wavelength detection on the liquid phase under the excitation of ultraviolet light with the same wavelengths and establishing the multi-component direct-competitive immunoassay method for quickly detecting the haptens labeled by the quantum dots of the various target analyte micromolecule organic matters according to the principle that the ratio of the characteristic fluorescence intensity of labeling the haptens by using the ratio of the fluorescence intensity of the different quantum dots in a prototype system to the fluorescence intensity of corresponding blank control is proportional to the concentration of a corresponding target analyte.

The invention discloses a histamine immunoassay method based on the characteristics of platinum-gold bimetallic nano-particle peroxidase. The method comprises the following steps: S1, labeling a histamine monoclonal antibody with a platinum-gold nano-particle to prepare a platinum-gold standard antibody nano-probe; S2, adding a sample to be tested and the nano-probe obtained in step S1 to an ELISAplate coated with a histamine antigen, and forming an antigen and platinum-gold standard antibody immune compound in a competitive immunoassay mode; S3, adding a coloring substrate solution containing 3,3',5,5'-tetramethylbenzidine and hydrogen peroxide to the ELISA plate, performing color development, and terminating the color development with sulfuric acid; and S4, detecting the absorbance at 450 nm by a the absorption of 450 nm was measured by an enzyme-linked immunometric meter to achieve the quantitative detection of histamine in the sample. The method has the advantages of easiness in operation, high sensitivity, good stability and high sample throughput, is suitable for rapid high-throughput screening of the histamine in foods, and has a great application prospect.

The invention relates to a new fluoroimmunoassay method for human thymidine kinase fluoroimmunoassay based on magnetic nanometer grains. The invention sets up a quick and simple immunological detecting technology for the high flux human thymidine kinase (hTK1), and the technology is used for the hTK1 clinical examination. The hTK1 is fixed with covalence on the surface of an amido silanization superparamagnetism nanometer grain immobilized carrier through glutaric dialdehyde, a competitive immunoassay method is adopted, horse radish peroxidase is used as an enzyme labeling, ethyl-para-hydroxyphenyl acid is used as a fluorogenic substrate, thereby realizing the detecting for the hTK1. The amido silanization nucleocapsid-shaped magnetic nanometer grains are evenly dispersed in liquidoid, thereby having the advantages of fixation and uniformity, high specificity, good repeatability, quick reaction velocity, etc., under the action of an adscititious magnetic field, the invention can effectively realize the separation and enrichment of the immune complex and the reaction liquid of the nucleocapsid-shaped magnetic nanometer grains, the operation of the analytical method is simple, accurate, sensitive and fast, automatic detection is easy to be realized, and large batch of test task can be completed.

The invention discloses a method for improving the sensitivity of competitive immunoassay. The method is mainly characterized in that a micromolecular substance to be detected is fully reacted with an antibody / receptor firstly and then reacted with a second molecule which participates in competition and is located on a solid phase in a short time, thus the sensitivity of the competitive immunoassay can be greatly improved. The method disclosed by the invention has the advantages of simplicity in operation, low cost, no need of expensive equipment and professional technicians, high sensitivity, and applicability to a plurality of immunoassay methods.

The invention is a method of identifying the presence of a disease state in a mammal which is associated with degradation of connective tissue in the mammal which contains the protein known as YKL-40. The method is a competitive immunoassay for YKL-40. It can be used, for example, to identify the presence of inflammatory or degenerative joint disease and tumor metastasis (to the extent it can be correlated to serum YKL-40 levels). Serum YKL-40 levels as detected and quantified by the inventive method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and / or metastasis of their cancers.

A competitive immunoassay, dye and method for rapidly detecting the presence of one or more target ligands within a fluid sample suspected of containing such ligand or ligands. The immunoassay comprises a protein-binding membrane, a first absorbent pad, a second absorbent pad, and a third absorbent pad. The protein-binding membrane has at least two regions of antibodies bound thereto for detecting dissimilar ligands. The second absorbent pad has formed therein a colloidal gold tracer having one, and preferably two or more ligand analog protein complexes adhering thereto. To utilize the system, the immunoassay strip is placed within a fluid sample. To the extent the target ligand is absent, a visual indicator will be provided signaling such absence. To the extent the target ligand is present at or above a threshold level, no such visual signal will be produced.

The invention is a method for determining in the amount of an analyte (An) in a sample. The method comprises competitive immunoassays and enzymatic assays in which a soluble product (immune complex and enzymatic product, respectively) is formed. The product is subsequently measured in a measuring zone of a microchannel structure of a microfluidic device.